20-F: Pharming Group Reports Strong 2025 Revenue Growth, Advances Pipeline

Pharming Group N.V. reported significant revenue growth in 2025, driven by strong sales of RUCONEST and Joenja, alongside strategic pipeline advancements and the acquisition of Abliva AB.

Summary

• Total revenues increased by 26.6% to $376.1 million in 2025, up from $297.2 million in 2024.
• RUCONEST sales in the U.S. market grew by 26% to $317.9 million in 2025, compared to $252.2 million in 2024, driven by a 20% increase in unit sales volume.
• Joenja (leniolisib) revenues increased by 29% to $58.2 million in 2025, up from $45.0 million in 2024, with the U.S. contributing $50.1 million.
• Operating profit turned positive at $25.8 million in 2025, a significant improvement from an operating loss of $8.6 million in 2024.
• Net profit for the year was $2.5 million in 2025, compared to a net loss of $11.8 million in 2024.
• The company completed the acquisition of Abliva AB in February 2025, gaining full ownership by June 2025, adding napazimone (KL1333) to its late-stage pipeline.
• Napazimone (KL1333) is in a pivotal clinical trial (FALCON) for mtDNA-driven primary mitochondrial disease, which passed a blinded interim futility analysis in 2024.
• Joenja received marketing authorization in Japan for adult and pediatric patients aged 4 years and older in March 2026, marking the first global approval for children aged 4 to 11.
• The company received a Complete Response Letter (CRL) from the FDA in January 2026 for the sNDA seeking approval of Joenja for children aged 4 to 11 years, requesting additional pharmacokinetic data and clarification on an analytical method.
• Remediation efforts successfully addressed previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2025.
• Net cash flows from operating activities significantly improved to $54.7 million in 2025, from a net cash outflow of $1.8 million in 2024.
• The company withdrew RUCONEST from commercialization in non-U.S. markets in November 2025, as these markets represented less than 2% of RUCONEST revenue and were not financially sustainable long-term.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, reflecting significant financial growth, successful pipeline expansion through acquisition, and effective remediation of internal control issues. While regulatory delays for pediatric Joenja and increased R&D costs are noted, the overall trajectory and strategic execution are favorable.

Positives

• Total revenues increased by 26.6% to $376.1 million in 2025, demonstrating strong top-line growth.
• Operating profit turned positive to $25.8 million in 2025 from a loss in 2024, indicating improved operational efficiency and profitability.
• Net profit for the year reached $2.5 million in 2025, a significant turnaround from previous losses.
• RUCONEST sales in the U.S. increased by 26% to $317.9 million, maintaining its role as a reliable cash generator.
• Joenja (leniolisib) revenues grew by 29% to $58.2 million, with strong uptake in the U.S. and a successful launch in the U.K.
• The acquisition of Abliva AB strengthened the late-stage pipeline with napazimone (KL1333), a potential first-in-disease therapy for primary mitochondrial disease.
• The pivotal FALCON study for napazimone (KL1333) passed a blinded interim futility analysis, indicating potential for benefit at final analysis.
• Joenja received marketing authorization in Japan for adult and pediatric patients aged 4 years and older, expanding its global reach and patient access.
• The company successfully remediated all previously disclosed material weaknesses in internal control over financial reporting by December 31, 2025.
• Net cash flows from operating activities showed a substantial increase to $54.7 million in 2025, reflecting improved underlying cash generation.

Negatives

• Research and development costs increased by 20.7% to $100.4 million in 2025, primarily due to the napazimone (KL1333) program.
• General and administrative activities costs increased by 13.2% to $80.0 million in 2025, partly due to severance expenses and acquisition-related costs.
• Marketing and sales activities costs increased by 10.3% to $131.0 million in 2025, driven by commercial expansion.
• The FDA issued a Complete Response Letter (CRL) for Joenja's sNDA for pediatric patients aged 4-11 years, requesting additional PK data and analytical method clarification.
• The withdrawal of RUCONEST from non-U.S. markets, while strategic, represents a reduction in the product's global commercial footprint.
• Interest income from marketable securities decreased by $2.7 million in 2025 due to reduced investments and declining interest rates.
• Other finance expenses increased by $8.2 million to $18.1 million, mainly due to foreign currency effects from the weakening U.S. dollar against the Euro.

Risks

• Intense competition for RUCONEST from existing and developing HAE treatments, including new prophylactic and gene therapies, could reduce market penetration and profitability.
• Heavy dependence on RUCONEST sales in the United States, making the business vulnerable to adverse events or manufacturing constraints related to the product.
• Potential for unexpected safety or efficacy concerns with newly approved Joenja, which could lead to regulatory actions, product recalls, or reduced market acceptance.
• Commercial success of approved products and product candidates depends on market acceptance by physicians, patients, and payors, which is not guaranteed.
• Inability to maintain and grow sales and marketing capabilities, particularly outside the U.S., or to secure favorable third-party agreements, could adversely affect business.
• Failure to maintain or obtain adequate coverage, reimbursement levels, and pricing policies from governmental authorities and health insurers could limit marketability and revenue generation.
• Limited resources may lead to foregoing or delaying opportunities with product candidates or indications that later prove to have greater commercial potential.
• High degree of uncertainty and risk in the costs and timing of clinical trials, filings, and approvals for novel approaches, making product development difficult to predict.
• Reliance on third parties for preclinical studies and clinical trials, with risks of failure to carry out duties, meet deadlines, or comply with regulatory requirements.
• FDA may not accept data from clinical trials conducted outside the United States, potentially requiring additional costly and time-consuming trials.
• Inability to obtain or maintain orphan drug exclusivity for products or product candidates, or competitors obtaining such exclusivity, could limit market access.
• Clinical trial results may not be sufficiently robust to support marketing approval, potentially requiring additional trials or extended follow-up periods.
• Vulnerability to cyberattacks that could compromise sensitive information, prevent access to critical data, and expose the company to liability and reputational harm.
• Contamination in the manufacturing process, raw material shortages, or supplier failures could cause delays in clinical development or commercial supply.
• Dependence on a limited number of suppliers for essential components and materials, risking supply disruptions and adverse impacts on product delivery and clinical trials.
• Significant customer concentration, with two U.S. specialty pharmacies accounting for 77% of revenues, poses risks if these customers experience declining sales or financial instability.
• Challenges in obtaining and protecting proprietary technology rights, with patents potentially being challenged, deemed unenforceable, invalidated, or circumvented.
• Changes in trade policies, including tariffs and other import/export restrictions, could adversely affect business operations and costs.
• Fluctuations in exchange rates, particularly between the Euro and U.S. dollar, may adversely affect financial results due to global operations.
• Adverse capital and credit market conditions, including rising interest rates, could affect liquidity, access to capital, and cost of capital.
• Negative public opinion and increased regulatory scrutiny of transgenic manufacturing techniques or ethical treatment of livestock could damage public perception and sales.
• Inaccurate assumptions and estimates regarding disease prevalence and addressable markets could materially affect revenues and cash position.
• Non-compliance with U.S. and foreign export/import controls, sanctions, anti-corruption, and anti-money laundering laws could lead to criminal liability and other serious consequences.
• Failure to comply with U.K., EU, or U.S. privacy and data security laws (e.g., GDPR, HIPAA) could result in civil/criminal penalties and other liability.
• Relationships with healthcare professionals, customers, and payors are subject to anti-kickback, fraud and abuse, privacy, and transparency laws, risking significant penalties.
• Failure to comply with Medicaid Drug Rebate Program or other governmental pricing programs could lead to additional reimbursement requirements, penalties, and fines.
• Regulatory approval is limited to specific indications, and promotion for unapproved (off-label) uses could result in significant fines and reputational damage.
• Current and future healthcare legislative reform measures may adversely affect business and results of operations by reducing reimbursement or increasing regulatory burdens.
• Misconduct or illegal activity by employees and independent contractors could lead to regulatory sanctions, reputational harm, and significant financial impact.
• Failure or perceived failure to achieve environmental, social, and governance (ESG) objectives could adversely affect reputation, business, and stock price.
• As a foreign private issuer, the company is exempt from certain U.S. securities laws and Nasdaq rules, potentially offering less protection to investors.
• Future sales of ordinary shares or ADSs, or the perception of such sales, could depress prices and impair ability to raise additional capital.
• Rights of shareholders and ADS holders are governed by Dutch law, which may differ from U.S. jurisdictions and offer less protection.
• Provisions of Articles of Association or Dutch corporate law might deter acquisition bids or attempts to change the board of directors.
• Shareholders and ADS holders may experience substantial dilution upon future issuances of ordinary shares due to limited preemptive rights.
• The company does not comply with all best practice provisions of the Dutch Corporate Governance Code, potentially affecting shareholder rights.
• No dividends are anticipated in the foreseeable future, meaning returns depend solely on share price appreciation.
• ADS holders may not receive distributions if it is illegal or impractical to make them available.
• Dividends to certain related parties in low-taxed jurisdictions might become subject to additional Dutch withholding tax.
• ADS holders must act through the depositary to exercise voting rights, potentially leading to delays.
• Trading of ordinary shares on Euronext Amsterdam and ADSs on Nasdaq may adversely affect liquidity and value, and exchange rate movements can impact prices.
• Difficulty in effecting service of process on the company or certain directors/officers in the U.S. or enforcing U.S. judgments in the Netherlands.
• ADS holders may not be entitled to a jury trial for claims under the deposit agreement, potentially leading to less favorable results.
• Limitations on transfer of ADSs by the depositary.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. holders.
• Risk of being treated as a Controlled Foreign Corporation (CFC) for U.S. federal income tax purposes, leading to adverse tax consequences for certain U.S. shareholders.

Future Outlook

Pharming Group expects continued growth and durability for RUCONEST, midterm momentum driven by Joenja, and disciplined advancement of leniolisib and napazimone (KL1333) pipeline assets. The company intends to grow Joenja in APDS through intensified patient-finding and ex-U.S. approvals and launches, while pursuing pediatric label expansion. Regulatory decisions for Joenja in the European Economic Area are expected in Q2 2026, and a decision in Canada is anticipated by mid-year 2026. Top-line data from two Phase II leniolisib studies in PIDs with immune dysregulation are expected in the second half of 2026. The pivotal FALCON study for napazimone (KL1333) is on track for a late 2027 readout, with regulatory submissions potentially following thereafter. The company anticipates further investments in the acquired pipeline over the coming years, which will temporarily reduce cash resources and affect results in 2026.

Management Comments

• Fabrice Chouraqui, CEO, is responsible for Pharming's strategy and day-to-day operations, guiding its continued growth as a global rare disease company.
• The company is committed to advancing care for people living with rare and ultra-rare diseases, focusing on areas of significant unmet need where scientific and commercial expertise can make a meaningful difference.
• Management believes that investments in commercialization and pipeline development will support continued growth following approvals.
• The company remains confident in the robustness of RUCONEST sales, growth and expansion of Joenja sales, and the expansion of its pipeline.

Industry Context

StockSavvy.ai notes that Pharming Group's strategic focus on rare and ultra-rare diseases, particularly in primary immunodeficiencies (PIDs) and mitochondrial diseases, aligns with a growing trend in the pharmaceutical industry towards specialized, high-value therapeutic areas. The increasing prevalence of prophylactic therapies in the HAE market, as highlighted by new FDA approvals in 2025, intensifies the competitive landscape for acute treatments like RUCONEST, necessitating strong differentiation. The acquisition of Abliva AB and its lead asset napazimone (KL1333) positions Pharming in the underserved mitochondrial disease space, a market with significant unmet need and long-term growth potential. The company's efforts to expand genetic testing and reclassify variants of uncertain significance (VUSs) for APDS reflect a broader industry push for earlier and more precise diagnosis in rare genetic conditions.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.

Related Party Transactions

• Paid BioConnection $5.4 million for fill and finish services in 2025 (compared to $4.6 million in 2024 and $4.7 million in 2023).
• Owed BioConnection $1.3 million for fill and finish services as of December 31, 2025.
• Entered into management contracts with certain executive officers (including executive directors) and service contracts with non-executive directors, containing customary provisions like confidentiality and non-competition.
• Entered into indemnity agreements with each director and executive officer, in line with the Articles of Association, requiring indemnification to the fullest extent permitted by law.
• Adopted a Related Party Transaction Policy requiring Board or independent committee approval for material related party transactions.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved profitability, and pipeline advancements, but potential dilution from future equity raises and risks associated with foreign private issuer status and Dutch corporate law.
• Patients: Expanded access to Joenja in new markets (U.K., Japan, Australia, Israel) and ongoing efforts for pediatric label expansion, as well as advancement of napazimone (KL1333) for primary mitochondrial disease, offer new treatment options.
• Employees: Increased employee costs due to bonuses and commercial organization expansion, but also restructuring activities leading to a 20% net reduction in non-commercial and non-medical headcount.
• Healthcare Providers: Continued demand for RUCONEST and Joenja, with efforts to educate the medical community on product benefits and support diagnostic testing for APDS.
• Suppliers/Partners: Continued reliance on third-party manufacturers and suppliers, with risks related to supply chain disruptions and quality control procedures. Transactions with BioConnection continue for fill and finish services.
• Regulatory Bodies: Ongoing engagement with FDA, EMA, MHLW, MHRA, Health Canada, and SFDA for regulatory approvals and compliance, including addressing a Complete Response Letter for Joenja pediatric sNDA.

Next Steps

• Await European Commission (EC) approval decision for Joenja (leniolisib) in the EU in Q2 2026.
• Await regulatory decision from Health Canada for Joenja (leniolisib) by mid-year 2026.
• Anticipate top-line data readouts from two Phase II leniolisib studies in PIDs with immune dysregulation in the second half of 2026.
• Continue Wave 2 enrollment and progress the pivotal FALCON clinical study for napazimone (KL1333), with readout anticipated in late 2027.
• Engage with the FDA to address the Complete Response Letter (CRL) for Joenja's pediatric sNDA and prepare for resubmission.
• Commercial launch of Joenja in Japan is expected following agreement with the MHLW on the National Health Insurance drug price.
• Continue efforts to characterize disease-causing impact of VUSs in APDS genes and determine overall prevalence of APDS.
• Strengthen platform enablers including quality, supply reliability, data, and analytics, while maintaining financial discipline in 2026.

Key Dates

Recommendation

Pharming Group demonstrated strong financial performance in 2025 with significant revenue growth and a return to profitability, driven by its key commercial products, RUCONEST and Joenja. The strategic acquisition of Abliva AB and the advancement of the napazimone (KL1333) pipeline asset provide future growth potential in high-unmet-need areas. However, the company faces substantial R&D expenditures, competitive pressures in the HAE market, and regulatory hurdles, as evidenced by the FDA's Complete Response Letter for pediatric Joenja. While the financial health is improving and the pipeline is promising, these ongoing risks and the need for continued significant investment suggest a 'hold' recommendation for investors, balancing current positive momentum with future uncertainties and execution risks.

Keywords

Pharming Group, RUCONEST, Joenja, leniolisib, Hereditary Angioedema, HAE, Activated Phosphoinositide 3-kinase Delta Syndrome, APDS, Primary Mitochondrial Disease, PMD, napazimone, KL1333, Biotechnology, Rare Diseases, Orphan Drug, Clinical Trials, Regulatory Approval, SEC Filing, Financial Results, Pipeline, Abliva AB, Novartis, YungJin Pharm Co., Ltd., Immunological Disorders, Genetic Conditions, PI3K inhibition, C1-INH, NAD/NADH modulation